National Institute for Health and Care Excellence Guidance

The Management of Atrial Fibrillation

http://www.nice.org.uk/guidance/CG180

Atrial Fibrillation Quality Standard

www.nice.org.uk/guidance/qs93

Venous thromboembolism: reducing the risk: Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital

http://www.nice.org.uk/guidance/CG92

Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing

http://www.nice.org.uk/guidance/CG144

Quality Standard for diagnosis and management of thromboembolic diseases

http://www.nice.org.uk/quality/QS29

NICE Pathways – Mapping the guidance

This online tool provides quick and easy access, topic by topic, to the range of guidance from NICE, including quality standards, technology appraisals, clinical, public health and social care guidelines and NICE implementation tools.

http://pathways.nice.org.uk/

Atrial fibrillation and heart valve disease:self monitoring coagulaton status using point-of-care coagulometers (the CoaguChek XS system and the INRatio2 PT/INR monitor)

http://www.nice.org.uk/guidance/dg14

 

Apixaban

Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
http://www.nice.org.uk/guidance/TA245

Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
http://www.nice.org.uk/guidance/TA275

Apixaban for the treatment and secondary prevention of deep vein thrombosis and /or pulmonary embolism

http://www.nice.org.uk/guidance/TA341

Dabigatran

Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
http://www.nice.org.uk/guidance/TA157

Dabigatran extexilate for preventing stroke and systemic embolism in people with nonvavlular atrial fibrillation
http://www.nice.org.uk/guidance/TA249

Dabigatran Etexilate for the treatment and secondary prevention of deep vein thrombosis and /or pulmonary embolism
http://www.nice.org.uk/guidance/TA327

Edoxaban

Edoxaban for preventing stroke and systemic embolism in people with non-valuvular atrial fibrillation

http://www.nice.org.uk/guidance/TA355

Edoxaban for treating and preventing deep vein thrombosis and pulmonary embolism

http://www.nice.org.uk/guidanceTA354

 

Rivaroxaban

Rivaroxaban for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
http://www.nice.org.uk/guidance/TA170

Rivaroxaban for preventing stroke and systemic embolism in people with nonvavlular atrial fibrillation
http://www.nice.org.uk/guidance/TA256

Rivaroxaban for treating deep vein thrombosis and preventing recurrent deep vein thrombosis and pulmonary embolism after a diagnosis of acute deep vein thrombosis in adults
http://www.nice.org.uk/guidance/TA261

Rivaroxaban treatment of acute symptomatic pulmonary embolism with or with or without symptomatic deep vein thrombosis and the prevention of recurrent VTE events
http://www.nice.org.uk/guidance/TA561

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

http://www.nice.org.uk/guidance/TA335

 

Scottish Medicines Consortium ADVICE

SMC advice relating to Apixaban, Dabigatran, Edoxaban  and Rivaroxaban and their indications can be found in the SMC Advice Directory
http://www.scottishmedicines.org.uk/Home